Disclaimer

The information we provide may include references to a Genentech product or use of a Genentech product that the FDA has not approved; because the FDA has not approved such product(s) or use, no conclusions regarding safety or efficacy may be made.

FENtrepid Phase III Study in PPMS

FENtrepid is the first PPMS study to use ocrelizumab as an active comparator

FENtrepid [NCT04544449]

Patient population

- PPMS diagnosis, aged 18–65 years
- EDSS score of 3.0–6.5 at screening

Double-blind treatment
(1:1 randomization)

Treatment	Active Comparator
Fenebrutinib	Ocrelizumab*

Primary endpoint: cCDP12†



■ cCDP12† MRI

Patients discontinuing treatment enter **safety follow-up**
OLE ≈96 weeks (optional)

*Dose 1 infusions are 14 days apart; then subsequent doses every 6 months.

†12-week composite confirmed disability progression (cCDP12) is a composite outcome measure defined as the first occurence of: a CDP-EDSS confirmed at 12 weeks OR a sustained increase of at least 20% from baseline in T25FWT score OR a sustained increase of at least 20% from baseline in 9-HPT score. CDP-EDSS is defined as a sustained increase of ≥1.0 points from baseline scores ≤5.5 (or ≥0.5 points from baseline EDSS scores ≥6.0).

BL, baseline; cCDP12, composite confirmed disability progression at 12 weeks; EDSS, Expanded Disability Status Scale; FEN, fenebrutinib; MRI, magnetic resonance imaging; OLE, open-label extension; Q12Wk, every 12 weeks.

MS.Hauser S, et al. Presented at MSVirtual 2020 (P0211).

Genentech
A Member of the Roche Group